DaVita (NYSE:DVA) Sets New 52-Week High – Should You Buy?

DaVita Inc. (NYSE:DVA)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $169.64 and last traded at $169.73, with a volume of 161278 shares changing hands. The stock had previously closed at $166.24.

Analysts Set New Price Targets

A number of analysts recently issued reports on DVA shares. Barclays increased their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial increased their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Stock Performance

The company has a market capitalization of $13.93 billion, a price-to-earnings ratio of 18.33, a P/E/G ratio of 0.83 and a beta of 0.92. The company has a 50 day moving average price of $158.13 and a 200 day moving average price of $153.57. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.85 EPS. Equities research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently added to or reduced their stakes in DVA. Caprock Group LLC bought a new stake in DaVita in the 4th quarter worth about $200,000. Mediolanum International Funds Ltd purchased a new stake in shares of DaVita during the fourth quarter valued at approximately $868,000. SteelPeak Wealth LLC bought a new stake in DaVita during the fourth quarter worth $1,045,000. Nilsine Partners LLC boosted its position in DaVita by 0.8% in the fourth quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock worth $1,669,000 after purchasing an additional 92 shares during the last quarter. Finally, KBC Group NV raised its stake in shares of DaVita by 0.8% during the 4th quarter. KBC Group NV now owns 316,155 shares of the company’s stock worth $47,281,000 after purchasing an additional 2,636 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.